On December 19, 2025 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported the oral presentation of interim data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The VB-C-03 trial is investigating abi-suva in combination with KEYTRUDA (pembrolizumab) in 1st line unresectable recurrent or metastatic head and neck cancer patients (NCT06016920). Nykode is further advancing abi-suva development in 1st line head and neck cancer through the Abili-T phase 2 randomized controlled trial.
Presentation details:
Location: ICHNO 2026, Seville, Spain
Date: March 20, 2026
Time: 15:15-16:15 (CET)
The abstract is expected to be published on February 19, 2026.
Michael Engsig, Chief Executive Officer of Nykode, commented: "As previously announced, we look forward to providing further insight into the C-03 clinical data from 1st line head and neck cancer patients which supported our recently communicated strategy to further investigate abi-suva in this population with significant unmet needs."
(Press release, Nykode Therapeutics, DEC 19, 2025, View Source [SID1234661560])